Discover trends, market shifts, and competitive outlooks for the multiple myeloma drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has The Multiple Myeloma Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In the past few years, the multiple myeloma drugs market has experienced a robust growth. It is projected to rise from a value of $21.84 billion in 2024 to reach $23.25 billion in 2025, growing at a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this exceptional growth during the historical period include enhanced diagnosis procedures, successful clinical trials, increased understanding of the disease biology, improvements in healthcare infrastructure, patient advocacy, and heightened awareness.
In the coming years, the multiple myeloma drugs market is anticipated to witness substantial growth, reaching a value of $29.99 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.6%. This expected growth over the forecast period can be attributed to developments in immunotherapy, the expansion of targeted therapies, the uses of liquid biopsy, the rise of car-t cell therapy, and discovery of biomarkers. In the same period, prominent trends would include a shift towards long-term survivorship, the examination of epigenetic therapies, a broader role for telemedicine, wider access to novel therapies, and sustainability in myeloma care.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp
Which Primay Drivers Are Accelerating Growth in the Multiple Myeloma Drugs Market?
The surge in hematological cancer instances is anticipated to propel the multiple myeloma drugs market’s expansion. Hematological malignancies originate in blood-forming tissues like bone marrow, or cells of the immune system like leukemia, lymphoma, multiple myeloma, among others. Drugs for multiple myeloma are commonly employed in the treatment of various forms of myeloma by inhibiting and destroying cancer cells, reducing the cell division process, stimulating different enzymatic activities, and aiding in strengthening bones and alleviating pain in the weakened bone. For instance, in January 2023, the American Cancer Society (ACS), a health organization committed to eradicating cancer in the US, reported about 59,610 new leukemia cases and nearly 20,380 acute myeloid leukemia (AML) instances. Furthermore, the death toll associated with leukemia was approximately 23,710. Consequently, the rising frequency of hematological cancer is fuelling the growth of the multiple myeloma drugs market.
Which Primary Segments of the Multiple Myeloma Drugs Market Are Driving Growth and Industry Transformations?
The multiple myeloma drugs market covered in this report is segmented –
1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types
2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Men, Women
Subsegments:
1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib
3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin
4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab
5) By Steroids: Dexamethasone, Prednisone
6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=11943&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Multiple Myeloma Drugs Market?# Market?
North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Multiple Myeloma Drugs Industry Dynamics?
One of the leading trends emerging in the multiple myeloma drugs market is product innovation. Various dominant companies in the field are putting their focus on creating unique and effective products to consolidate their market presence and secure a competitive edge. In a significant development in March 2022, Janssen Biotech Inc., a renowned biotech firm based in Japan, got approval from the United States Food and Drug Administration for Carvykti. Carvykti is a CAR T-Cell therapy, an individualized immunotherapy for multiple myeloma. It (ciltacabtagene autoleucel) is a tailor-made cell product based on genetic modifications. The product comprises of T cells transduced in vitro with a non-replicating lentiviral vector that conveys an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR). It contains two singular domain antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. It’s eligible for patients who have undergone through at least four instances of therapy involving three types of critical multiple myeloma medications, such as an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, especially designed to treat relapsed conditions.
View the full report here:
https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report
What Parameters Are Used to Define the Multiple Myeloma Drugs Market?
Multiple myeloma drugs refer to medications utilized to treat multiple myeloma and cancer-impacting plasma cells (white blood cells found in the bone marrow). These drugs are employed to address bone-related issues such as myeloma, pamidronate (Aredia), and zoledronic acid (Zometa) in an individual.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11943
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
